IDEXX Laboratories (IDXX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $4.27
- Estimate
- $3.93
- Surprise
- +8.5%
- Revenue (period 2026-06-30)
- $1.22B
- Score today
- 5.6/10
Revenue source: xbrl.
How the report landed
IDEXX Laboratories (IDXX) beat the $3.93 estimate with adjusted EPS of $4.27 — a clear 8.5% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates IDXX Buy (Wait) at 5.6/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +8.5% surprise compares with a +5.8% four-quarter average. Next scheduled report: 2026-11-02.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.4 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Supplier: Ortho-Clinical Diagnostics
- Thin upside margin: 5.9%
- Earnings in 4 days (event risk)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $570.23
- Entry target
- $556.69
- Price target
- $604.14
- Stop
- $530.97
- Upside to target
- +5.9%
- Reward-to-risk
- 0.5:1
The stock trades at 39.6× trailing but 33.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 74 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
IDXX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $44.40B
- P/E (fwd)
- 33.6
- P/E (ttm)
- 39.6
- 52-week range
- $500.61–$769.98
- Off 52-week high
- 25.9%
- RSI (14)
- 74
- Volume vs avg
- 0.08×
- Score today
- 5.6/10